Epilepsy Research and Medical Cannabis Overview

Research Overview

This roundup features summaries of recent peer-reviewed studies found in PubMed, the database maintained by the U.S. National Library of Medicine. While these studies are published in respected medical journals, the information presented here is for general education only and does not constitute medical advice. The science regarding cannabis in seizure management is still evolving, and patients should always consult with a licensed physician for personalized medical guidance.

The Landscape of Epilepsy and CBD

Epilepsy affects approximately 50 million people worldwide, and nearly 30% of those patients experience seizures that are resistant to multiple antiepileptic drugs. In this context, cannabidiol (CBD)—a nonpsychoactive chemical extracted from cannabis—is an emerging candidate of interest. A review in JAMA noted that about 27% of adults in the U.S. and Canada have used cannabis for medical purposes, with 10.5% of the U.S. population reporting CBD use for therapeutic reasons. The FDA has approved cannabinoid products for conditions including HIV/AIDS-related anorexia, chemotherapy-induced nausea, and specific pediatric seizure disorders.

CBD in Severe, Drug-Resistant Epilepsy

For patients with severe and drug-resistant epilepsy, cannabidiol has shown efficacy in certain conditions like Dravet syndrome and Lennox-Gastaut syndrome. However, a systematic review in CNS drugs found that evidence across the broader spectrum of developmental and epileptic encephalopathies remains fragmented. A review in Seizure further examined how CBD might influence neuronal pathways, including neurotransmitter systems, ion channels, and neuroinflammatory pathways, making it a subject of study for those whose seizures do not respond to standard medications.

Safety and Emerging Concerns

While some cannabinoid products have received approval, safety remains a key focus in the research. The drug Epidiolex, which is CBD-based and approved for certain childhood-onset epilepsy, carries a warning about liver toxicity. Research in Archives of Toxicology examined cytotoxicity in liver cells and identified cell cycle disturbances and endoplasmic reticulum stress associated with CBD and its metabolites.

Biological Pathways and Channel Studies

Understanding the underlying mechanisms of seizure control is a major goal of these studies. A review in Neural Regeneration Research looked at the role of voltage-gated sodium channels — specifically the Nav1.1, Nav1.2, and Nav1.6 subtypes — in modulating neuronal excitability and signal transmission across the nervous system. Additionally, research in Epilepsia examined how antiepileptic medications may modulate interictal epileptiform discharges — which are markers of neuronal activity — and the potential implications for cognition and behavior.

As this field continues to develop, these peer-reviewed summaries provide one view of the ongoing research. For any questions regarding treatment or the use of CBD, please speak with your doctor.